Trump announced a generic drug tariff plan. No details exist. The news cycle demands we pretend this matters anyway.
Generic drugs cost pennies to manufacture. They're expensive in America because pharmacy benefit managers skim 40% off every transaction while pretending to negotiate on your behalf. Tariffs won't fix that. They'll make it worse. But retail traders just loaded up on shares of Viatris and Teva because the headline contained the word "manufacturing" and their brains completed a circuit that shouldn't have connected.
The plan raises questions about prices and supply chains. It answers none of them. Classic Trump policy rollout. Announce something vague. Let cable news fill six hours of airtime with speculation. Watch pharmaceutical lobbyists write the actual bill in a basement somewhere while everyone argues about nothing.
Domestic manufacturers stand to gain if this happens. Foreign manufacturers stand to lose. Both groups will spend millions lobbying. The final legislation will somehow benefit neither while costing consumers more. You'll pay $47 for a bottle of ibuprofen that costs nine cents to produce and wonder why technical analysis didn't predict this.
The real genius is packaging protectionism as healthcare reform. American factories will totally come back this time. Just like every other time a politician promised manufacturing jobs would return if we just made foreign goods more expensive. Your bloodwork medication will cost double but at least the factory will be in Ohio instead of India. Freedom isn't free. It's $340 a month plus your insurance deductible.
Somewhere a day trader is calculating the beta on generic drugmaker stocks using a YouTube tutorial and a calculator he stole from his kid's pencil case.
Photo by Çağlar Oskay on Unsplash
Leave a Comment